Brokerages predict that Dextera Surgical Inc. (NASDAQ:DXTR) will post earnings of ($0.06) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Dextera Surgical’s earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.05). Dextera Surgical posted earnings of ($0.41) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 85.4%. The business is expected to issue its next quarterly earnings report on Tuesday, February 6th.

According to Zacks, analysts expect that Dextera Surgical will report full-year earnings of ($0.25) per share for the current year, with EPS estimates ranging from ($0.28) to ($0.21). For the next fiscal year, analysts anticipate that the company will post earnings of ($0.21) per share, with EPS estimates ranging from ($0.22) to ($0.20). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Dextera Surgical.

Dextera Surgical (NASDAQ:DXTR) last announced its quarterly earnings data on Thursday, November 9th. The medical instruments supplier reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.02). The firm had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.62 million.

Several analysts have recently issued reports on DXTR shares. Zacks Investment Research raised shares of Dextera Surgical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Ladenburg Thalmann Financial Services assumed coverage on shares of Dextera Surgical in a research note on Wednesday, August 16th. They set a “buy” rating and a $0.80 price objective for the company.

Shares of Dextera Surgical (NASDAQ DXTR) remained flat at $$0.15 during midday trading on Friday. 1,033,500 shares of the company’s stock traded hands, compared to its average volume of 3,644,360. Dextera Surgical has a 52 week low of $0.11 and a 52 week high of $2.33.

Several large investors have recently bought and sold shares of the stock. Perkins Capital Management Inc. acquired a new position in Dextera Surgical during the second quarter worth $100,000. Virtu KCG Holdings LLC lifted its holdings in shares of Dextera Surgical by 1,380.6% in the second quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock worth $111,000 after acquiring an additional 344,933 shares during the last quarter. Finally, Broadfin Capital LLC lifted its holdings in shares of Dextera Surgical by 64.7% in the second quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 388,080 shares during the last quarter. Institutional investors and hedge funds own 6.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at

About Dextera Surgical

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Get a free copy of the Zacks research report on Dextera Surgical (DXTR)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Dextera Surgical (NASDAQ:DXTR)

Receive News & Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.